Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier in the course of illness. The severe respiratory disease developed in 13 of 80 patients who received convalescent plasma. The trial was stopped early at 76% of its projected sample size. No solicited adverse events were observed.
